Search filters

List of works by Scott Metcalfe

A kick in the butt: time to address tobacco waste in New Zealand

scientific article published on 2 June 2017

Assessing the value for money of pharmaceuticals in New Zealand--PHARMAC's approach to cost-utility analysis

scientific article published on 12 July 2013

Balancing the Risks and Benefits of Celecoxib

scientific article published on 1 June 2007

Child abuse in Australian camps-whose business, and who should speak out?

scientific article

Climate science, denial and the Declaration of Delhi

scientific article

Combating antimicrobial resistance demands nation-wide action and global governance

scientific article

Comment on "ahead of its time? Reflecting on New Zealand's Pharmac following its 20th anniversary" : clarification from PHARMAC: PHARMAC takes no particular distributive approach (utilitarian or otherwise)

scientific article published in October 2014

Comments on "Simoens, S. Health economic assessment: a methodological primer. Int. J. Environ. Res. Public Health 2009, 6, 2950-2966"-New Zealand in fact has no cost-effectiveness threshold

scientific article published on 20 April 2010

Direct-to-consumer advertising--yes it can compromise patient health

scientific article published on September 12, 2003

Dispensing patterns for antidiabetic agents in New Zealand: are the guidelines being followed?

scientific article

Do pharmaceutical score cards give us the answers we seek?

scientific article published on November 25, 2011

Fast, fair climate action crucial for health and equity

article

Funding a clinical trial: the perspective of a medicines funder

scientific article published on 1 January 2008

Generic pregabalin; current situation and implications for health authorities, generics and biosimilars manufacturers in the future

article

Global governance is a key part of the solution to antimicrobial resistance (response to Gravatt)

scientific article

Going against the flow: the impact of PHARMAC not funding COX-2 inhibitors for chronic arthritis

scientific article

Health and equity impacts of climate change in Aotearoa-New Zealand, and health gains from climate action

scientific article

Mind the gap: An analysis of foregone health gains from unfunded cancer medicines in New Zealand

scientific article

More about cardiovascular disease and lipid management in New Zealand

scientific article

More on PHARMAC and tobacco control in New Zealand

scientific article published on 27 January 2006

National prescribing data for dabigatran

scientific article published on March 9, 2012

New Zealand's emissions trading scheme and health: wasting our opportunities

scientific article published on 30 October 2008

Old letters, new rules

scholarly article

Our advice? Get a budget!

scientific article published on 1 January 2002

Over and under? Ethnic inequities in community antibacterial prescribing

scientific article published on 18 January 2019

PHARMAC and EpiPen for anaphylaxis

scientific article published on 23 June 2006

PHARMAC and erythropoietin for cancer patients

scientific article published on 23 June 2006

PHARMAC and statins--correction is needed

scientific article published on 2 March 2007

PHARMAC and statins--getting the best population health gains

scientific article published on 21 July 2006

PHARMAC and tobacco control in New Zealand: two licensed funded options are already available

scientific article published on 24 June 2005

PHARMAC funding of 9-week concurrent trastuzumab (Herceptin) for HER2-positive early breast cancer

scientific article

PHARMAC has no cost-effectiveness threshold

scientific article published on February 24, 2012

PHARMAC measures savings elsewhere to the health sector

scientific article

PHARMAC responds on Herceptin assumptions and decisions

scientific article published on 24 August 2007

PHARMAC responds on TNF inhibitors for inflammatory arthritis

scientific article published on 16 December 2005

PHARMAC responds on agents to prevent osteoporotic fractures

scientific article published on 10 March 2006

PHARMAC responds on long-acting inhalers for COPD

scientific article

PHARMAC responds on long-acting insulin analogues

scientific article published on 28 October 2005

PHARMAC responds on salbutamol

scientific article published on 26 August 2005

PHARMAC responds on treatments for pulmonary arterial hypertension

scientific article published on 16 December 2005

PHARMAC responds to Richard Milne on discounting health benefits and costs

scientific article published on 29 July 2005

PHARMAC responds to Stewart Mann on dihydropyridine calcium channel antagonists

scientific article published on 12 August 2005

PHARMAC welcomes debate

scientific article published on 15 July 2005

PHARMAC's response on gemcitabine and transparency

scientific article

PHARMAC's response on temozolomide and funding costly medicines that prolong life shortly

scientific article published on 16 December 2005

PHARMAC's updated guidelines for cost-effectiveness analyses, with new discount rate

scientific article published on 20 July 2007

PHARMAC's updated guidelines for cost-utility analyses, with new QALYs per $1M metric

scientific article published on 29 July 2012

Response from PHARMAC: difficult choices

scientific article published on 14 March 2003

Response to Cameron et al "Mind the graph" Semin Oncol. 2018 [in press]

article

Response to letter to the editor on 'Mind the gap'

scientific article published on 14 September 2017

Self-monitoring blood glucose test strip use with diabetes medicines in people with types 1 and 2 diabetes in New Zealand

scientific article published on 28 November 2014

Seretide meta-analysis missed important features and overstates any advantages over concurrent LABA/ICS devices

scientific article published in March 2004

Sign On - prescribing for climate health

scientific article published on 30 October 2009

Specific oral contraceptive use and venous thromboembolism resulting in hospital admission

scientific article published on 26 November 2004

Systematic review of celecoxib for osteoarthritis and rheumatoid arthritis. Celecoxib's relative gastrointestinal safety is overstated

scholarly article

Te Wero tonu-the challenge continues: Māori access to medicines 2006/07-2012/13 update

scholarly article

Terminations of pregnancy associated with isotretinoin use in New Zealand

scientific article published on July 29, 2011

The Zero Carbon Bill and the health of New Zealanders-help shape this crucial health law now

scientific article published on 13 July 2018

Time for healthy investment

scientific article published on 27 October 2017

Trastuzumab: possible publication bias

scientific article published on 01 May 2008

Usage and equity of access to isotretinoin in New Zealand by deprivation and ethnicity

scientific article published on November 25, 2011

Variation in the use of medicines by ethnicity during 2006/07 in New Zealand: a preliminary analysis

scientific article

Why New Zealand must rapidly halve its greenhouse gas emissions

scientific article

Paulina is supported by:

About Paulina

Help